Population pharmacokinetics of recombinant factor IX: Implications for dose tailoring

Haemophilia

Volumn 19, Issue 5, 2013, Pages 753-757

  Bjorkman S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Dosing; Factor IX; Haemophilia B; Pharmacokinetics; Prophylaxis.

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CHILD; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

DOSING; FACTOR IX; HAEMOPHILIA B; PHARMACOKINETICS; PROPHYLAXIS.;

ADOLESCENT; ADULT; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR IX; HEMOPHILIA B; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84883052367     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12188     Document Type: Article

References (11)

1. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003; 9(Suppl. 1): 101-10.
2. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10.
3. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 2010; 16: 597-605.
4. Björkman S, Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180-2.
5. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-84.
6. Udata C, Sullivan S, Kelly P, Roth DA, Meng X. Population pharmacokinetic modeling of BeneFIX in pediatric and adult patients with hemophilia B demonstrates weight as an important factor contributing to inter-patient PK variability. Blood 2008; 112: Abstract 1218.
7. Björkman S, Shapiro AD, Berntorp E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001; 7: 133-9.
8. Björkman S, Åhlén V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis. Eur J Clin Pharmacol 2012; 68: 969-77.
9. Centers for Disease Control and Prevention. Clinical Growth Charts. Atlanta, GA. Available at http://www.cdc.gov/growthcharts/. Accessed July 30, 2012.
10. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range of 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009; 65: 989-98.
11. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 4th edn. Baltimore: Lippincott Williams & Wilkins, 2011.